▶ 調査レポート

経口血糖降下薬の世界市場 2020年:メーカー別、地域別、種類・用途別

• 英文タイトル:Global Oral Hypoglycemic Drugs Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが調査・発行した産業分析レポートです。経口血糖降下薬の世界市場 2020年:メーカー別、地域別、種類・用途別 / Global Oral Hypoglycemic Drugs Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 / D0804-09382資料のイメージです。• レポートコード:D0804-09382
• 出版社/出版日:GlobalInfoResearch / 2020年7月
• レポート形態:英文、PDF、101ページ
• 納品方法:Eメール(納期2~3日)
• 産業分類:医薬品・治療
• 販売価格(消費税別)
  Single User¥361,920 (USD3,480)▷ お問い合わせ
  Multi User¥542,880 (USD5,220)▷ お問い合わせ
  Corporate User¥723,840 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、経口血糖降下薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。経口血糖降下薬の種類別市場規模(スルホニル尿素(SU)、二重グアニジン、グルコシダーゼ阻害剤、インスリン相乗剤)、用途別市場規模(病院、クリニック、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・市場概要
・メーカー情報(販売量、市場シェア、製品概要、SWOT分析):Pfizer、Takeda Pharmaceuticals、GlaxoSmithKline、AstraZeneca、Sanofi、Johnson & Johnson、Servier Laboratories、Eli Lilly、Merck & Co、Novo Nordisk、Boehringer Ingelheim、Bristol-Myers Squibb
・地域別グローバル市場分析 2015年-2020年
・経口血糖降下薬の北米市場(アメリカ、カナダ、メキシコ)
・経口血糖降下薬のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・経口血糖降下薬のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・経口血糖降下薬の南米市場(ブラジル、アルゼンチン)
・経口血糖降下薬の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:スルホニル尿素(SU)、二重グアニジン、グルコシダーゼ阻害剤、インスリン相乗剤
・用途別分析:病院、クリニック、その他
・地域別市場規模予測 2021年-2025年
・販売チャネル、流通業者、代理店
・調査の結果・結論

Market Overview
The Oral Hypoglycemic Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The most likely (base case) scenario is that the global Oral Hypoglycemic Drugs sales will be xx in 2020 from Oral Hypoglycemic Drugs million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Oral Hypoglycemic Drugs market size is expected to grow at xx% or more annually for the next five years.

This report also researches and evaluates the impact of Covid-19 outbreak on the Oral Hypoglycemic Drugs industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Oral Hypoglycemic Drugs and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Market segmentation
Oral Hypoglycemic Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Oral Hypoglycemic Drugs market has been segmented into
Sulfonylureas (SU)
Double Guanidine
Glucosidase Inhibitor
Insulin Synergist

By Application, Oral Hypoglycemic Drugs has been segmented into:
Hospital
Clinic
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Oral Hypoglycemic Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Oral Hypoglycemic Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Oral Hypoglycemic Drugs market.

The report offers in-depth assessment of the growth and other aspects of the Oral Hypoglycemic Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Competitive Landscape and Oral Hypoglycemic Drugs Market Share Analysis
Oral Hypoglycemic Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Oral Hypoglycemic Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Oral Hypoglycemic Drugs sales, revenue and market share for each player covered in this report.

The major players covered in Oral Hypoglycemic Drugs are:
Pfizer
Takeda Pharmaceuticals
GlaxoSmithKline
AstraZeneca
Sanofi
Johnson & Johnson
Servier Laboratories
Eli Lilly
Merck & Co
Novo Nordisk
Boehringer Ingelheim
Bristol-Myers Squibb

Among other players domestic and global, Oral Hypoglycemic Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Oral Hypoglycemic Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Oral Hypoglycemic Drugs, with price, sales, revenue and global market share of Oral Hypoglycemic Drugs in 2018 and 2019.
Chapter 3, the Oral Hypoglycemic Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Oral Hypoglycemic Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Oral Hypoglycemic Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Oral Hypoglycemic Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

1 Market Overview
1.1 Oral Hypoglycemic Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Oral Hypoglycemic Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Sulfonylureas (SU)
1.2.3 Double Guanidine
1.2.4 Glucosidase Inhibitor
1.2.5 Insulin Synergist
1.3 Market Analysis by Application
1.3.1 Overview: Global Oral Hypoglycemic Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Overview of Global Oral Hypoglycemic Drugs Market
1.4.1 Global Oral Hypoglycemic Drugs Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
1.6 COVID-19 Outbreak: Oral Hypoglycemic Drugs Industry Impact
1.6.1 COVID-19 Potential Implications for the Oral Hypoglycemic Drugs
1.6.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Oral Hypoglycemic Drugs
1.6.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.6.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.6.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.6.2 Opportunity Analysis in Covid-19 Crisis
1.6.3 Market Risk and Restraints
1.6.4 Market Driving Force
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Takeda Pharmaceuticals
2.2.1 Takeda Pharmaceuticals Details
2.2.2 Takeda Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Takeda Pharmaceuticals SWOT Analysis
2.2.4 Takeda Pharmaceuticals Product and Services
2.2.5 Takeda Pharmaceuticals Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 GlaxoSmithKline SWOT Analysis
2.3.4 GlaxoSmithKline Product and Services
2.3.5 GlaxoSmithKline Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 AstraZeneca
2.4.1 AstraZeneca Details
2.4.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 AstraZeneca SWOT Analysis
2.4.4 AstraZeneca Product and Services
2.4.5 AstraZeneca Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Sanofi
2.5.1 Sanofi Details
2.5.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Sanofi SWOT Analysis
2.5.4 Sanofi Product and Services
2.5.5 Sanofi Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Johnson & Johnson Product and Services
2.6.4 Johnson & Johnson Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Servier Laboratories
2.7.1 Servier Laboratories Details
2.7.2 Servier Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Servier Laboratories Product and Services
2.7.4 Servier Laboratories Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Eli Lilly
2.8.1 Eli Lilly Details
2.8.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Eli Lilly Product and Services
2.8.4 Eli Lilly Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Merck & Co
2.9.1 Merck & Co Details
2.9.2 Merck & Co Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Merck & Co Product and Services
2.9.4 Merck & Co Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Novo Nordisk
2.10.1 Novo Nordisk Details
2.10.2 Novo Nordisk Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Novo Nordisk Product and Services
2.10.4 Novo Nordisk Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Boehringer Ingelheim
2.11.1 Boehringer Ingelheim Details
2.11.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Boehringer Ingelheim Product and Services
2.11.4 Boehringer Ingelheim Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 Bristol-Myers Squibb
2.12.1 Bristol-Myers Squibb Details
2.12.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Bristol-Myers Squibb Product and Services
2.12.4 Bristol-Myers Squibb Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Oral Hypoglycemic Drugs Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Oral Hypoglycemic Drugs Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Oral Hypoglycemic Drugs Manufacturer Market Share in 2019
3.3.2 Top 6 Oral Hypoglycemic Drugs Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Oral Hypoglycemic Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Oral Hypoglycemic Drugs Sales and Market Share by Regions (2015-2020)
4.1.2 Global Oral Hypoglycemic Drugs Revenue and Market Share by Regions (2015-2020)
4.2 North America Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
4.3 Europe Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
4.5 South America Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Oral Hypoglycemic Drugs Sales, Revenue and Market Share by Country
5.1.1 North America Oral Hypoglycemic Drugs Sales and Market Share by Country (2015-2020)
5.1.2 North America Oral Hypoglycemic Drugs Revenue and Market Share by Country (2015-2020)
5.2 United States Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
5.3 Canada Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
5.4 Mexico Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Oral Hypoglycemic Drugs Sales, Revenue and Market Share by Country
6.1.1 Europe Oral Hypoglycemic Drugs Sales and Market Share by Country (2015-2020)
6.1.2 Europe Oral Hypoglycemic Drugs Revenue and Market Share by Country (2015-2020)
6.2 Germany Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
6.3 UK Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
6.4 France Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
6.5 Russia Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
6.6 Italy Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Oral Hypoglycemic Drugs Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Oral Hypoglycemic Drugs Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Oral Hypoglycemic Drugs Revenue and Market Share by Regions (2015-2020)
7.2 China Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
7.3 Japan Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
7.4 Korea Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
7.5 India Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
7.7 Australia Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Oral Hypoglycemic Drugs Sales, Revenue and Market Share by Country
8.1.1 South America Oral Hypoglycemic Drugs Sales and Market Share by Country (2015-2020)
8.1.2 South America Oral Hypoglycemic Drugs Revenue and Market Share by Country (2015-2020)
8.2 Brazil Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
8.3 Argentina Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Oral Hypoglycemic Drugs Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Oral Hypoglycemic Drugs Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Oral Hypoglycemic Drugs Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
9.3 Turkey Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
9.5 South Africa Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Oral Hypoglycemic Drugs Sales and Market Share by Type (2015-2020)
10.2 Global Oral Hypoglycemic Drugs Revenue and Market Share by Type (2015-2020)
10.3 Global Oral Hypoglycemic Drugs Price by Type (2015-2020)
11 Global Oral Hypoglycemic Drugs Market Segment by Application
11.1 Global Oral Hypoglycemic Drugs Sales Market Share by Application (2015-2020)
11.2 Global Oral Hypoglycemic Drugs Revenue Market Share by Application (2015-2020)
11.3 Global Oral Hypoglycemic Drugs Price by Application (2015-2020)
12 Market Forecast
12.1 Global Oral Hypoglycemic Drugs Sales, Revenue and Growth Rate (2021-2025)
12.2 Oral Hypoglycemic Drugs Market Forecast by Regions (2021-2025)
12.2.1 North America Oral Hypoglycemic Drugs Market Forecast (2021-2025)
12.2.2 Europe Oral Hypoglycemic Drugs Market Forecast (2021-2025)
12.2.3 Asia-Pacific Oral Hypoglycemic Drugs Market Forecast (2021-2025)
12.2.4 South America Oral Hypoglycemic Drugs Market Forecast (2021-2025)
12.2.5 Middle East & Africa Oral Hypoglycemic Drugs Market Forecast (2021-2025)
12.3 Oral Hypoglycemic Drugs Market Forecast by Type (2021-2025)
12.3.1 Global Oral Hypoglycemic Drugs Sales Forecast by Type (2021-2025)
12.3.2 Global Oral Hypoglycemic Drugs Market Share Forecast by Type (2021-2025)
12.4 Oral Hypoglycemic Drugs Market Forecast by Application (2021-2025)
12.4.1 Global Oral Hypoglycemic Drugs Sales Forecast by Application (2021-2025)
12.4.2 Global Oral Hypoglycemic Drugs Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US

List of Tables
Table 1. Global Oral Hypoglycemic Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Oral Hypoglycemic Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Oral Hypoglycemic Drugs Market Size and Growth Estimation in Various Scenarios in 2020
Table 4. Global Oral Hypoglycemic Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 5. Market Opportunities in Next Few Years
Table 6. Market Risks Analysis
Table 7. Market Drivers
Table 8. Pfizer Basic Information, Manufacturing Base and Competitors
Table 9. Pfizer Oral Hypoglycemic Drugs Major Business
Table 10. Pfizer Oral Hypoglycemic Drugs Total Revenue (USD Million) (2018-2019)
Table 11. Pfizer SWOT Analysis
Table 12. Pfizer Oral Hypoglycemic Drugs Product and Services
Table 13. Pfizer Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 14. Takeda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 15. Takeda Pharmaceuticals Oral Hypoglycemic Drugs Major Business
Table 16. Takeda Pharmaceuticals Oral Hypoglycemic Drugs Total Revenue (USD Million) (2018-2019)
Table 17. Takeda Pharmaceuticals SWOT Analysis
Table 18. Takeda Pharmaceuticals Oral Hypoglycemic Drugs Product and Services
Table 19. Takeda Pharmaceuticals Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 20. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 21. GlaxoSmithKline Oral Hypoglycemic Drugs Major Business
Table 22. GlaxoSmithKline Oral Hypoglycemic Drugs Total Revenue (USD Million) (2018-2019)
Table 23. GlaxoSmithKline SWOT Analysis
Table 24. GlaxoSmithKline Oral Hypoglycemic Drugs Product and Services
Table 25. GlaxoSmithKline Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 26. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 27. AstraZeneca Oral Hypoglycemic Drugs Major Business
Table 28. AstraZeneca Oral Hypoglycemic Drugs Total Revenue (USD Million) (2018-2019)
Table 29. AstraZeneca SWOT Analysis
Table 30. AstraZeneca Oral Hypoglycemic Drugs Product and Services
Table 31. AstraZeneca Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 32. Sanofi Basic Information, Manufacturing Base and Competitors
Table 33. Sanofi Oral Hypoglycemic Drugs Major Business
Table 34. Sanofi Oral Hypoglycemic Drugs Total Revenue (USD Million) (2018-2019)
Table 35. Sanofi SWOT Analysis
Table 36. Sanofi Oral Hypoglycemic Drugs Product and Services
Table 37. Sanofi Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 38. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 39. Johnson & Johnson Oral Hypoglycemic Drugs Major Business
Table 40. Johnson & Johnson Oral Hypoglycemic Drugs Total Revenue (USD Million) (2018-2019)
Table 41. Johnson & Johnson SWOT Analysis
Table 42. Johnson & Johnson Oral Hypoglycemic Drugs Product and Services
Table 43. Johnson & Johnson Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 44. Servier Laboratories Basic Information, Manufacturing Base and Competitors
Table 45. Servier Laboratories Oral Hypoglycemic Drugs Major Business
Table 46. Servier Laboratories Oral Hypoglycemic Drugs Total Revenue (USD Million) (2018-2019)
Table 47. Servier Laboratories SWOT Analysis
Table 48. Servier Laboratories Oral Hypoglycemic Drugs Product and Services
Table 49. Servier Laboratories Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 50. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 51. Eli Lilly Oral Hypoglycemic Drugs Major Business
Table 52. Eli Lilly Oral Hypoglycemic Drugs Total Revenue (USD Million) (2018-2019)
Table 53. Eli Lilly SWOT Analysis
Table 54. Eli Lilly Oral Hypoglycemic Drugs Product and Services
Table 55. Eli Lilly Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 56. Merck & Co Basic Information, Manufacturing Base and Competitors
Table 57. Merck & Co Oral Hypoglycemic Drugs Major Business
Table 58. Merck & Co Oral Hypoglycemic Drugs Total Revenue (USD Million) (2018-2019)
Table 59. Merck & Co SWOT Analysis
Table 60. Merck & Co Oral Hypoglycemic Drugs Product and Services
Table 61. Merck & Co Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 62. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 63. Novo Nordisk Oral Hypoglycemic Drugs Major Business
Table 64. Novo Nordisk Oral Hypoglycemic Drugs Total Revenue (USD Million) (2018-2019)
Table 65. Novo Nordisk SWOT Analysis
Table 66. Novo Nordisk Oral Hypoglycemic Drugs Product and Services
Table 67. Novo Nordisk Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 68. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 69. Boehringer Ingelheim Oral Hypoglycemic Drugs Major Business
Table 70. Boehringer Ingelheim Oral Hypoglycemic Drugs Total Revenue (USD Million) (2018-2019)
Table 71. Boehringer Ingelheim SWOT Analysis
Table 72. Boehringer Ingelheim Oral Hypoglycemic Drugs Product and Services
Table 73. Boehringer Ingelheim Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 74. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 75. Bristol-Myers Squibb Oral Hypoglycemic Drugs Major Business
Table 76. Bristol-Myers Squibb Oral Hypoglycemic Drugs Total Revenue (USD Million) (2018-2019)
Table 77. Bristol-Myers Squibb SWOT Analysis
Table 78. Bristol-Myers Squibb Oral Hypoglycemic Drugs Product and Services
Table 79. Bristol-Myers Squibb Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 80. Global Oral Hypoglycemic Drugs Sales by Manufacturer (2018-2019) (K Units)
Table 81. Global Oral Hypoglycemic Drugs Revenue by Manufacturer (2018-2019) (USD Million)
Table 82. Global Oral Hypoglycemic Drugs Sales by Regions (2015-2020) (K Units)
Table 83. Global Oral Hypoglycemic Drugs Sales Market Share by Regions (2015-2020)
Table 84. Global Oral Hypoglycemic Drugs Revenue by Regions (2015-2020) (USD Million)
Table 85. North America Oral Hypoglycemic Drugs Sales by Countries (2015-2020) (K Units)
Table 86. North America Oral Hypoglycemic Drugs Sales Market Share by Countries (2015-2020)
Table 87. North America Oral Hypoglycemic Drugs Revenue by Countries (2015-2020) (USD Million)
Table 88. North America Oral Hypoglycemic Drugs Revenue Market Share by Countries (2015-2020)
Table 89. Europe Oral Hypoglycemic Drugs Sales by Countries (2015-2020) (K Units)
Table 90. Europe Oral Hypoglycemic Drugs Sales Market Share by Countries (2015-2020)
Table 91. Europe Oral Hypoglycemic Drugs Revenue by Countries (2015-2020) (USD Million)
Table 92. Asia-Pacific Oral Hypoglycemic Drugs Sales by Regions (2015-2020) (K Units)
Table 93. Asia-Pacific Oral Hypoglycemic Drugs Sales Market Share by Regions (2015-2020)
Table 94. Asia-Pacific Oral Hypoglycemic Drugs Revenue by Regions (2015-2020) (USD Million)
Table 95. South America Oral Hypoglycemic Drugs Sales by Countries (2015-2020) (K Units)
Table 96. South America Oral Hypoglycemic Drugs Sales Market Share by Countries (2015-2020)
Table 97. South America Oral Hypoglycemic Drugs Revenue by Countries (2015-2020) (USD Million)
Table 98. South America Oral Hypoglycemic Drugs Revenue Market Share by Countries (2015-2020)
Table 99. Middle East & Africa Oral Hypoglycemic Drugs Sales by Countries (2015-2020) (K Units)
Table 100. Middle East & Africa Oral Hypoglycemic Drugs Sales Market Share by Countries (2015-2020)
Table 101. Middle East & Africa Oral Hypoglycemic Drugs Revenue by Countries (2015-2020) (USD Million)
Table 102. Middle East & Africa Oral Hypoglycemic Drugs Revenue Market Share by Countries (2015-2020)
Table 103. Global Oral Hypoglycemic Drugs Sales by Type (2015-2020) (K Units)
Table 104. Global Oral Hypoglycemic Drugs Sales Share by Type (2015-2020)
Table 105. Global Oral Hypoglycemic Drugs Revenue by Type (2015-2020) (USD Million)
Table 106. Global Oral Hypoglycemic Drugs Revenue Share by Type (2015-2020)
Table 107. Global Oral Hypoglycemic Drugs Sales by Application (2015-2020) (K Units)
Table 108. Global Oral Hypoglycemic Drugs Sales Share by Application (2015-2020)
Table 109. Global Oral Hypoglycemic Drugs Sales Forecast by Regions (2021-2025) (K Units)
Table 110. Global Oral Hypoglycemic Drugs Market Share Forecast by Regions (2021-2025)
Table 111. Global Oral Hypoglycemic Drugs Sales Forecast by Type (2021-2025) (K Units)
Table 112. Global Oral Hypoglycemic Drugs Market Share Forecast by Type (2021-2025)
Table 113. Global Oral Hypoglycemic Drugs Sales Forecast by Application (2021-2025)
Table 114. Global Oral Hypoglycemic Drugs Market Share Forecast by Application (2021-2025)
Table 115. Direct Channel Pros & Cons
Table 116. Indirect Channel Pros & Cons
Table 117. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Oral Hypoglycemic Drugs Picture
Figure 2. Global Sales Market Share of Oral Hypoglycemic Drugs by Type in 2019
Figure 3. Sulfonylureas (SU) Picture
Figure 4. Double Guanidine Picture
Figure 5. Glucosidase Inhibitor Picture
Figure 6. Insulin Synergist Picture
Figure 7. Oral Hypoglycemic Drugs Sales Market Share by Application in 2018
Figure 8. Hospital Picture
Figure 9. Clinic Picture
Figure 10. Others Picture
Figure 11. Global Oral Hypoglycemic Drugs Market Status and Outlook (2015-2025) (USD Million)
Figure 12. United States Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Canada Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Mexico Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Germany Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 16. France Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 17. UK Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Russia Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Italy Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 20. China Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Japan Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Korea Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 23. India Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Southeast Asia Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Australia Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 26. Brazil Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Egypt Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Saudi Arabia Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 29. South Africa Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Turkey Oral Hypoglycemic Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Global Oral Hypoglycemic Drugs Sales Market Share by Manufacturer in 2019
Figure 32. Global Oral Hypoglycemic Drugs Revenue Market Share by Manufacturer in 2019
Figure 33. Top 3 Oral Hypoglycemic Drugs Manufacturer (Revenue) Market Share in 2019
Figure 34. Top 6 Oral Hypoglycemic Drugs Manufacturer (Revenue) Market Share in 2019
Figure 35. Key Manufacturer Market Share Trend
Figure 36. Global Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 37. Global Oral Hypoglycemic Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 38. Global Oral Hypoglycemic Drugs Revenue Market Share by Regions (2015-2020)
Figure 39. Global Oral Hypoglycemic Drugs Revenue Market Share by Regions in 2018
Figure 40. North America Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
Figure 41. Europe Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
Figure 43. South America Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
Figure 44. Middle East & Africa Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020)
Figure 45. North America Oral Hypoglycemic Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 46. North America Oral Hypoglycemic Drugs Sales Market Share by Countries (2015-2020)
Figure 47. North America Oral Hypoglycemic Drugs Sales Market Share by Countries in 2018
Figure 48. North America Oral Hypoglycemic Drugs Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 49. North America Oral Hypoglycemic Drugs Revenue Market Share by Countries in 2018
Figure 50. United States Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 51. Canada Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 52. Mexico Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 53. Europe Oral Hypoglycemic Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 54. Europe Oral Hypoglycemic Drugs Revenue Market Share by Countries (2015-2020)
Figure 55. Europe Oral Hypoglycemic Drugs Revenue Market Share by Countries in 2019
Figure 56. Germany Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 57. UK Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 58. France Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 59. Russia Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 60. Italy Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 61. Asia-Pacific Oral Hypoglycemic Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 62. Asia-Pacific Oral Hypoglycemic Drugs Sales Market Share by Regions 2019
Figure 63. Asia-Pacific Oral Hypoglycemic Drugs Revenue Market Share by Regions 2019
Figure 64. China Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 65. Japan Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 66. Korea Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 67. India Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 68. Southeast Asia Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 69. South America Oral Hypoglycemic Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 70. South America Oral Hypoglycemic Drugs Sales Market Share by Countries in 2019
Figure 71. South America Oral Hypoglycemic Drugs Revenue Market Share by Countries in 2019
Figure 72. Brazil Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 73. Argentina Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 74. Middle East and Africa Oral Hypoglycemic Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 75. Middle East and Africa Oral Hypoglycemic Drugs Sales Market Share by Countries in 2019
Figure 76. Middle East and Africa Oral Hypoglycemic Drugs Revenue Market Share by Countries (2015-2020)
Figure 77. Middle East and Africa Oral Hypoglycemic Drugs Revenue Market Share by Countries in 2019
Figure 78. Saudi Arabia Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 79. Egypt Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 80. Turkey Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 81. South Africa Oral Hypoglycemic Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 82. Global Oral Hypoglycemic Drugs Sales and Growth Rate (2021-2025) (K Units)
Figure 83. Global Oral Hypoglycemic Drugs Revenue and Growth Rate (2021-2025) (USD Million)
Figure 84. North America Sales Oral Hypoglycemic Drugs Market Forecast (2021-2025) (K Units)
Figure 85. Europe Sales Oral Hypoglycemic Drugs Market Forecast (2021-2025) (K Units)
Figure 86. Asia-Pacific Sales Oral Hypoglycemic Drugs Market Forecast (2021-2025) (K Units)
Figure 87. South America Sales Oral Hypoglycemic Drugs Market Forecast (2021-2025) (K Units)
Figure 88. Middle East & Africa Sales Oral Hypoglycemic Drugs Market Forecast (2021-2025) (K Units)
Figure 89. Sales Channel: Direct Channel vs Indirect Channel